TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endoscopic recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of positive and negative cytological imprints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip effort outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doors task outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RL/WM task outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Main complications during ICU stay
Endpoint domain: Adverse events/effects
Primary endpoint: Thermal Comfort Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Temperature Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aortic plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta of the WSRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting-toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in physician initiated smoking cessation counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with complications after diagnosis of Acute Calculous Cholecystitis
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody formation to NESP
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lower Extremity Functional Scale (LEFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Atopic dermatitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgE mediated food allergy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-IgE mediated food allergy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microdislodgement of leads
Endpoint domain: Adverse events/effects
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale, 2nd Edition (CY-BOCS-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale, 1st Edition (CY-BOCS-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: glycated hemoglobin (HbA1c) level of 6.0% or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: open conversion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: axis of astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Recidivism Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Ferric Carboxymaltose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulated ln (TNF-a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stimulated ln (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stimulated ln (IL-1b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MFSI-SF Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Vitality, SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Magnitude of nocebo effects on pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ectopic lipid accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting-state brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of mechanical ventilation (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum concentration/elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alternate Healthy Eating Index-2010 (AHEI-2010) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Analyte Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Analyte Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetabular component migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of Area of Nasal Telangiectasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ICU admission or ED mortality
Endpoint domain: Mortality/survival
Primary endpoint: Free Fatty Acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General safety and tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of individuals enrolling in an ACA plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response to oxaliplatin based chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tibial Nerve Cross-sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the plasma concentration curve from time 0 to the concentration at 24 hours (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally tolerated dose of orantinib
Endpoint domain: Adverse events/effects
Primary endpoint: Postdural Puncture Headache incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Benefit Rate (CR+PR+SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in visual analog score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistence of inactive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-child interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Infant growth status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving a Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants developing hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in QTcF (AUC0-8)/8 at Day 3: Lead V5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QTcF (AUC0-8)/8 at Day 3: Lead II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QTcF (AUC0-8)/8 at Day 3: Global Lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence/absence of grade II-IV acute Graft versus Host Disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Allergen-Induced Late Asthmatic Response (LAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Intervention Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PHQ-9 Score for depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PCL-5 Score for PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lesion Regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Average Daily Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the corrected QT interval (QTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurence of Death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of Cardiovascular Events and Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious Unexpected Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Severity of CHD Symptoms (Angina)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unprotected Sex
Endpoint domain: Adverse events/effects
Primary endpoint: Virologic response to antiretroviral therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plasma Concentration (AUC) of Cyclobenzaprine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Swallowing difficulties
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum concentration of total PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mood variability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Zero-defect performance in daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in scores from the Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Infectious Endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: accuracy of NBI videobronchoscopic biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed using a VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion assessed with a universal goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality measured using the Modified-UCLA Shoulder Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life assessed with the SPADI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: House Brackmann Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Morphine Dosage Required for Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Low Back Pain Intensity Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Asthma Exacerbations Per Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of patient-reported genitourinary and gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tumor hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Incisional Hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of press ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unmet supportive care needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Continuity of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Total gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: molecular scores (probability) of lung transplant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: molecular diagnoses of the MMDx-TBB system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nepean Dyspepsia Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quantity of abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quantity of total body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quantity of pericardial fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Melbourne Assessment of Unilateral Upper Limb Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phototoxicity Irritation Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Forced Expiratory Volume in First Second (FEV1) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Forced Vital Capacity (FVC) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity (FEV1/FVC) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Muscle protein synthesis (%FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of fasting blood LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total number of attempts to successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response rate (Partial response (PR) or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma phytanic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prolonged Abstinence From Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Abstinence Bioverified by Salivary Cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Abstinence From Marijuana Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Abstinence Bioverified by Oral Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with change of primary treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: delirium- and coma-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the crown (for Hall and conventional techniques)
Endpoint domain: Mortality/survival
Primary endpoint: Success of the atraumatic restorative technique
Endpoint domain: Mortality/survival
Primary endpoint: Treatment (restoration) survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Respiratory Distress Assessment Instrument (RDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Respiratory Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Global Impressions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corrected amblyopic logMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C percent change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood orphanin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood norepinephrine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial species composition of the fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional outcome (highest level of education attained and current occupation)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of subjects who passed the voiding trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Corneal florescence staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Nitrate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak Plasma Nitrite Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak Red Blood Cell (RBC) Iron-nitrosyl Hemoglobin (NO-Hb) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiovascular fatal and non-fatal events
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Post-ERCP pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Clinically Significant Displacement of DLTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous Humor Prednisolone Acetate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall quantity of pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Response in Albumin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Percent Fall in FEV1 After Exercise Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration-time profile (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for SpO2 level to reach 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of survival months
Endpoint domain: Mortality/survival
Primary endpoint: Minimum Number of Vaccine Doses Created
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change From Baseline in Pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composity of Major Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Semmes Weinstein monofilament examination (SWME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EORTC QoLCIPN20
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: WOSI score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: safety of administering CHM-CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One New Morphometric Vertebral Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of tofacitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Endothelium-dependent and endothelium-independent vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes